questionText: To ask the Secretary of State for Health and Social Care, whether his Department has had discussions with the Joint Committee on Vaccination and Immunisation on the cost-effectiveness methodology applied to meningococcal group B vaccines; and whether that methodology will take account of (a) NICE's updated threshold of £25,000 to £35,000 per quality-adjusted life year and (b) other changes to NICE’s standard cost-effectiveness thresholds.
answerText: The Department is working closely with the UK Health Security Agency (UKHSA) to ensure that the methodology used by the Joint Committee on Vaccination and Immunisation (JCVI) to assess the cost-effectiveness of vaccination programmes provides the informat...
heading: Meningitis: Vaccination